Cam Gallagher, Director at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 15,642 shares at $74.50 ($1.2M) on 2021-12-15, disclosed to the SEC on 2021-12-16.
Open-market sale of $1.2M ZNTL by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.28 | 3,001 | $214K | 18.5% |
| 2 | $71.28 | 3,001 | $214K | 18.5% |
| 3 | $72.01 | 1,100 | $79K | 6.8% |
| 4 | $73.35 | 1,900 | $139K | 12.0% |
| 5 | $74.50 | 1,117 | $83K | 7.2% |
| 6 | $74.50 | 1,117 |
| $83K |
| 7.2% |
| 7 | $76.07 | 311 | $24K | 2.0% |
| 8 | $77.24 | 520 | $40K | 3.5% |
| 9 | $78.21 | 1,524 | $119K | 10.3% |
| 10 | $78.21 | 1,524 | $119K | 10.3% |
| 11 | $78.97 | 527 | $42K | 3.6% |
| Total | $73.95 avg | 15,642 | $1.2M | 100% |
| Filing → |
| ZNTL | SELL | 2024-02-12 | $13K | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $267K | — | Filing → |
| ZNTL | SELL | 2023-05-31 | $1.5M | — | Filing → |